Spleen tyrosine kinase (SYK) plays a critical role in immune cell signaling pathways and has been reported as a biomarker for human hepatocellular carcinoma (HCC). We sought to investigate the mechanism by which SYK promotes liver fibrosis and to evaluate SYK as a therapeutic target for liver fibrosis. We evaluated the cellular localization of SYK and the association between SYK expression and liver fibrogenesis in normal, hepatitis B virus (HBV)-infected, hepatitis C virus (HCV)-infected and non-alcoholic steatohepatitis (NASH) liver tissue (n536, 127, 22 and 30, respectively). A polymerase chain reaction (PCR) array was used to detect the changes in transcription factor (TF) expression in hepatic stellate cells (HSCs) with SYK knockdown. The effects of SYK antagonism on liver fibrogenesis were studied in LX-2 cells, TWNT-4 cells, primary human HSCs, and three progressive fibrosis/cirrhosis animal models, including a CCL 4 mouse model, and diethylnitrosamine (DEN) and bile duct ligation (BDL) rat models. We found that SYK protein in HSCs and hepatocytes correlated positively with liver fibrosis stage in human liver tissue. HBV or HCV infection significantly increased SYK and cytokine expression in hepatocytes. Increasing cytokine production further induced SYK expression and fibrosis-related gene transcription in HSCs. Up-regulated SYK in HSCs promoted HSC activation by increasing the expression of specific TFs related to activation of HSCs. SYK antagonism effectively suppressed liver fibrosis via inhibition of HSC activation, and decreased obstructive jaundice and reduced HCC development in animal models. Conclusion: SYK promotes liver fibrosis via activation of HSCs and is an attractive potential therapeutic target for liver fibrosis and prevention of HCC development. (HEPATOLOGY L iver cirrhosis is a major global health problem and it accounts for more than 1 million deaths each year worldwide.
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(1) Liver fibrosis, excessive deposition of extracellular matrix (ECM) in the liver, is the result of the wound-healing response to chronic liver damage triggered by a variety of causes, including hepatitis virus infection, alcohol abuse, or nonalcoholic steatohepatitis, (2, 3) and is a precursor to cirrhosis.
Hepatic stellate cells (HSCs) are responsible for producing most of the ECM and play a central role in liver fibrogenesis. (2, 4) HSCs are quiescent and located in the space between hepatocytes and sinusoidal endothelium (space of Disse) as retinoid storage cells. (5) Liver injury or stimuli from the microenvironment activate quiescent HSCs leading to production and accumulation ECM, resulting in liver fibrosis. (3) 
Activated HSCs
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lose their retinoid stores, proliferate and produce large amounts of chemokines and cytokines that further increase ECM production. (6, 7) Currently, there are no approved drugs that reverse liver fibrosis, further highlighting an urgent clinical need for anti-fibrotic therapies. (8, 9) An agent that directly inactivates HSCs has potential to be an effective antifibrotic strategy. (10, 11) In this study, we report that spleen tyrosine kinase (SYK) is critical for HSC activation and may represent a therapeutic target for inactivation of HSCs.
SYK is a cytoplasmic nonreceptor tyrosine kinase expressed in either hematopoietic or epithelial cells. It plays a crucial role in diverse biological functions, including cellular adhesion, immune recognition, platelet activation, and vascular development. (12) Previous studies have identified a pathogenetic role for SYK in renal interstitial fibrosis, (13) rheumatoid arthritis and some types of leukemia. (14) (15) (16) (17) SYK has been demonstrated as a potential therapeutic target for some fibrosis-related diseases including scleroderma, renal fibrosis and rheumatoid arthritis. (18) (19) (20) However, the biological function of SYK in liver fibrosis has not been well characterized. In this study, we found that SYK is a key molecule in HSC activation and we demonstrated that SYK inhibitors blocked HSC activation, both in cell culture and in animal fibrosis models, including the CCl 4 -induced mouse, diethylnitrosamine (DEN)-induced rat, and bile duct ligation (BDL)-induced rat models. We found that SYK inhibitors effectively blocked HSC activation. In addition, we found that SYK inhibitors potently attenuated liver fibrosis and HCC development in animal models.
Materials and Methods
Detailed Materials and Methods are described in Supporting Information.
Results

UP-REGULATION OF SYK EXPRESSION IN HSCs AND HEPATOCYTES IS ASSOCIATED WITH LIVER FIBROSIS
To evaluate whether SYK expression is associated with liver fibrosis/cirrhosis, we analyzed the publiclyavailable National Cancer for Biotechnology Information Gene Expression Omnibus (GEO) database. We found that human SYK mRNA expression was significantly up-regulated by 7.52-fold (hepatitis B virus [HBV] infection), 2.19-fold (hepatitis C virus [HCV] infection), 1.96-fold (alcohol abuse) and 1.34-fold (non-alcoholic steatohepatitis, NASH) compared to normal liver ( Fig. 1A and Supporting Fig. S1 ). Moreover, SYK expression was up-regulated in liver tissues from infants with biliary atresia or other causes of intrahepatic cholestasis (Supporting Fig. S1 ). We further examined SYK expression by immunostaining in human liver tissue with confirmed fibrosis/cirrhosis. We found that SYK protein expression was markedly higher in HBV-infected (n5127), HCV-infected (n522), cholestasis (n57), and NASH (n530) liver tissue compared to normal liver (n536) tissue (P values all < 0.01; Fig. 1B and Supporting Fig. S1 ). Similar to the human data, murine fibrotic livers also demonstrated a significant increase in SYK and a-smooth muscle actin (ACTA2) mRNA and/or protein levels compared with controls in CCl 4 -induced mouse fibrosis, DEN-induced and BDL induced rat fibrosis models (Supporting Fig. S2 ). Furthermore, we analyzed co-localization in vivo of SYK with HNF4a, a-SMA, CK19, CD31, and CD68, which are cell markers of hepatocytes, activated HSCs, biliary tract cells, endothelial cells, and Kupffer cells, respectively. Compared to normal human liver, the enhanced SYK expression was mainly located in hepatocytes and HSCs of in human fibrotic livers (Fig. 1C) , but not in other liver cell types (Supporting Fig. S3 ).
We found higher levels of SYK mRNA and protein expression in HBV or HCV-infected hepatocytes compared to uninfected Huh7.5.1 cells (Fig. 1D , Supporting Fig. S4 ). Higher SYK expression was also observed in HSCs co-cultured with Japanese fulminant hepatitis 1 (JFH1) HCV-infected Huh7.5.1 compared to uninfected Huh7.5.1 cells (P < 0.001; Fig. 1E ).
Consistent with the results from our human fibrotic liver, we found that up-regulated SYK expression was mainly found in hepatocytes and HSCs by immunostaining of liver sections from CCl 4 -induced fibrotic mouse liver (Fig. 1F) . Furthermore, SYK expression was detected in activated HSCs isolated from CCl 4 -induced fibrotic liver, but not in primary HSCs isolated from normal liver (Fig. 1F ).
SYK PROMOTES HSC ACTIVATION
To assess whether SYK expression is related to HSC activation and liver fibrosis, we compared SYK mRNA and protein expression in isolated primary mouse HSCs (mHSCs) from day 2 to 14. It has been reported that isolated primary mHSCs plated on plastic gradually become activated within 2 weeks. (21) We found significantly higher HSC activation marker (ACTA2 and platelet derived growth factor receptor beta [PDGFRb] ) mRNA and protein expression at day 14 compared to day 3 after isolation ( Fig. 2A,B) . SYK expression was almost undetectable in the quiescent state early after mHSC isolation. However, we found high expression levels of both SYK and activated SYK [p-SYK (Y525/526)] in primary mHSCs with subsequent plate activation, CCl 4 -induced fibrotic mouse liver and their primary hepatocytes and HSCs ( Fig. 2A,B and Supporting Fig. S3E,F) . (22) Therefore, we cultured HSCs on Matrigel-coated plates to inactivate the cells. We found that Matrigel dramatically decreased SYK and activated SYK expression, along with the HSC activation markers a-SMA and PDGFRb, to nearly undetectable levels (Fig. 2C) . Moreover, SYK overexpression significantly promoted HSC activation and enhancement of ACTA2, PDGFRb, collagen type 1 alpha 1 (COL1A1), tissue inhibitor of metalloproteinase 1 (TIMP1), plasminogen activator inhibitor-1 (PAI-1) and transforming growth factor beta-1 (TGF-b1) expression (Supporting Fig. S5 ). Matrigel abrogated SYK overexpressioninduced HSC activation and the enhancement of fibrosis related gene mRNA and protein expression (Supporting Fig. S5 ). These findings suggest that HSC quiescence induced by Matrigel suppresses the effect of SYK on HSC activation.
In addition, we found that knockdown of SYK expression with small interfering RNA (siRNA) (siSYK) in LX-2 or TWNT-4 HSC lines significantly decreased mRNA and protein expression of activated HSC and fibrosis related genes, including a-SMA (ACTA2), PDGFRb, COL1A1, TIMP1, PAI-1 and TGF-b1 (Fig. 2D ). In contrast, overexpression of wild type (WT) or catalytically activated (CA) mutant SYK, but not kinase dead (KD) mutant SYK, significantly enhanced expression of these genes in HSCs ( We previously demonstrated that the SYK two main isoforms, SYK(L) and SYK(S), play different roles in HCC development. We found that both SYK(L) and SYK(S) mRNA were enhanced during fibrosis progression in the CCl 4 and DEN induced murine fibrotic liver, however, SYK(L) expressed higher level than SYK(S) (Supporting Fig. S7 ). Overexpression of SYK(L) or SYK(S) in LX-2 or TWNT-4 cells significantly increased HSC activation markers (ACTA2 and PDGFRb) and fibrosis associated genes (COL1A1, TIMP1, PAI-1 and TGF-b1). SYK(L) exerted stronger activation effects on liver fibrosis than SYK(S) (Supporting Fig. S8 ). These data indicate that both SYK(L) and SYK(S) promoted liver fibrosis, and that SYK(L) is a more potent inducer of liver fibrosis progression than SYK(S).
SYK PROMOTES HSC ACTIVATION VIA UP-REGULATION OF SPECIFIC TFs
It has been reported that the alternative expression of specific TFs is critical for HSC activation. (23) (24) (25) To further investigate whether SYK promoted HSC activation by regulating these transcription factors (TFs), we performed a TF PCR array to detect changes in expression of 84 TFs in LX-2 cells following SYK siRNA knockdown. We identified that 41 TFs were significantly down-regulated and 2 that were up- . Data presented are means 6 SD. NS 5 not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001. regulated more than 2-fold (P < 0.05) between SYK siRNA and control siRNA (Fig. 3A , Supporting Table  S1 ). We selected three well-reported HSC activation associated genes including the MYB proto-oncogene transcription factor (MYB), CREB binding protein (CBP) and MYC proto-oncogene (MYC), for further validation. MYB directly binds to the promoter region of the ACTA2 gene, increasing ACTA2 gene expression and further activating HSCs. (26) Both CBP and MYC are downstream molecules of the Wnt/bcatenin signaling pathway and play a key role in promoting HSC activation and proliferation. (27) (28) (29) We hypothesized that SYK promoted HSC activation via regulation of the expression of specific TFs. Our qPCR validation of these 3 TFs confirmed our PCR array results of downregulation of these TFs by SYK siRNA (Fig. 3A) . We found that siRNAs to MYB, CBP or MYC did not affect SYK expression compared to Neg siRNA in both LX2 and TWNT-4 cells. These results suggest that SYK lies upstream of MYB, CBP and MYC (Supporting Fig. S9 ). Furthermore, we found that siRNAs to SYK, MYB, CBP or MYC reduced expression of the HSC activation markers ACTA2 and PDGFRb in LX-2 and TWNT-4 cells, (Fig. 3B, Supporting Fig. S10 ). MYB siRNA blocked SYK overexpression-induced enhancement of MYB and ACTA2 expression in LX-2 and TWNT-4 cells (Fig. 3C) . These results indicate that SYK promotes HSC activation via up-regulation of these TFs.
MYC and CCND1 are important target effectors of the Wnt/b-catenin signaling pathway to promote the activation and proliferation of HSCs. (28, 29) Histone H3 lysine 9 acetylation (acetyl-H3K9) in the promotor region is important for both MYC and CCND1 expression. (30) We found that SYK siRNA significantly decreased MYC and CCND1 mRNA and protein expression in HSCs (Fig. 3D) . We performed chromatin immunoprecipitation (ChIP) analyses with an acetylation-H3K9 antibody to determine whether SYK regulates H3K9 acetylation of MYC and CCND1 promoter regions. We found that SYK shRNA and SYK inhibitor (GS-9973) treatment significantly decreased H3K9 acetylation in the CCND1 and MYC promoter regions in LX-2 cells. Moreover, overexpression of SYK-WT, but not SYK-KD in LX-2 cells significantly increased CCND1 and MYC promoter regions H3K9 acetylation and mRNA expression, respectively (Fig. 3E,F) .
UP-REGULATION OF SYK IN HEPATOCYTES PROMOTES HSC ACTIVATION VIA CROSSTALK
We investigated whether SYK up-regulation in hepatocytes promotes liver fibrosis via crosstalk between hepatocytes and HSCs. We utilized conditioned medium (CM) and a Transwell co-culture system to investigate crosstalk between hepatocytes and HSCs (Fig. 4A) . We found that JFH1 HCV infection significantly increased SYK, TGF-b1, PAI-1, CTGF and TIMP1 expression, while SYK siRNA blocked this HCV-induced up-regulation in JFH1-infected Huh7.5.1 cells (Fig. 4B) . To further investigate changes of cytokine by siSYK in JFH1-infected hepatocytes, we performed a PCR array, including 86 cytokine genes. The PCR array identified 10 cytokines with more than 2-fold expression change (P < 0.05) in JFH1-infected Huh7.5.1 cells by siSYK compared to its control. Of the ten cytokines, CXCL10, IL8, CXCL1, CXCL2, IL9, IL18, CCL20, IL12B and LIF were significantly down-regulated and CXCL12 was up-regulated (Supporting Table S2 ). Real-time PCR assays indicated that the change in expression of CXCL10, IL8, CXCL1, CXCL2, IL9, IL18, CCL20, and LIF, corresponding with the results of PCR array, but not IL12B and CXCL12 (Fig. 4C) . We selected CXCL10, IL8 and CXCL1 for further verification by ELISA, and the secreted levels of these cytokines in cell supernatants were decreased significantly (P < 0.001; Fig. 4D ). Moreover, when SYK-WT and SYK-KD were overexpressed in Huh7.5.1-JFH1 cells, only WT SYK increased the expression of these cytokines (Supporting Fig. S11 ). These results suggest that SYK promotes cytokine production in Huh7.5.1 cells. Furthermore, we found that SYK siRNA in Huh7.5.1-JFH1 cells significantly reduced, while overexpression of SYK significantly increased TIMP1, PAI-1 and TGF-b1 mRNA and protein levels compared to Neg siRNA in the supernatant when cocultured with LX2 cells (Fig. 4E,F) . In fact, activated HSCs expressed and secreted higher levels of TGFb1, PAI-1 and TIMP1 than hepatocytes (Supporting Fig. S12 ). Our results suggest that HCV infectioninduced SYK and cytokine production enhancement in hepatocytes promotes HSC activation through cytokine crosstalk between hepatocytes and HSCs.
SYK ANTAGONISM HAS ANTI-FIBROTIC ACTIVITY IN VITRO
GS-9973 is a selective and potent oral inhibitor of SYK (Supporting Fig. S13A) , (31) and has been in clinical evaluation for chronic lymphocytic leukemia. (32) We utilized GS-9973 to investigate whether SYK antagonism has anti-fibrotic activity. We found that GS-9973 treatment inhibited cell proliferation and HSC activation marker (ACTA2 and PDGFRb) expression in a dose and time dependent manner in LX-2 and TWNT-4 cells (Fig. 5A) . Our data indicated that 1.0 lM GS-9973 did not affect proliferation in both LX-2 and TWNT-4 cells and was thus selected for further experiments (Fig. 5A) . We confirmed that GS-9973 (1.0 lM) effectively inhibited SYK phosphorylation at Y525/526 (Fig. 5B) , the key activation site at the kinase domain of SYK. (33, 34) We also found that GS-9973 down-regulated protein expression of a-SMA, PDGFRb and PAI-1 (Fig.  5B ). These results demonstrate that SYK antagonism inhibits HSC activation and exerts an anti-fibrotic activity by inhibiting Y525/526 phosphorylation of SYK. Immunoprecipitation of SYK followed by immunoblotting indicated that both GS-9973 (1.0 lM) and protein phosphatase (PPase, as a positive control) completely inhibited Y525/526 phosphorylation of SYK, and decreased a-SMA and PDGFb expression in LX-2 and TWNT-4 cells (Fig. 5C ). GS-9973 also effectively decreased the secreted protein level of COL-1, TIMP1, PAI-1, TGF-b1, LN and HA in cultured supernatants of LX-2 and TWNT-4 cells (Fig. 5D ). Moreover, we observed similar antifibrotic activity of GS-9973 in primary human HSCs. Treatment of GS-9973 (1.0 lM) did not influence the proliferation of primary human HSCs (Fig. 5E ), but significantly decreased the mRNA level of HSC activation markers and protein levels of PAI-1 and TGFb1 in supernatants (Fig. 5F ).
In addition, we found another SYK antagonist, PRT062607 (2.0 lM), also significantly inhibited HSC activation, but with lower efficiency compared to GS-9973 (Supporting Fig. S13 ). Our results indicate that the SYK antagonists GS-9973 and PRT062607 exhibit anti-fibrotic activity in vitro.
SYK ANTAGONIST TREATMENT REDUCES FIBROSIS DEVELOPMENT IN THREE MURINE MODELS
We further tested the effects of the SYK inhibitor GS-9973 on liver fibrogenesis and hepatocellular carcinoma (HCC) transformation in three distinct animal fibrosis/cirrhosis models, the CCl 4 mouse, DEN rat and BDL rat models (Figs. 6A, 7A, and 8A ). In each model, two doses of GS-9973 were used (Supporting Figs. S14-S16). We successfully induced liver fibrosis and cirrhosis in all three animal models. The median Ishak fibrosis scores were 5.0 (interquartile range [IQR] 4.0-6.0) for the CCl 4 mouse model, and 6.0 (IQR 4.0-6.0) for the DEN and BDL rat models. GS-9973 significantly reduced Ishak fibrosis scores, and Sirius red, a-SMA and p-SYK (Y525/526) staining compared to vehicle controls in all three animal models (all P < 0.01; Fig. 6C , 7C and 8B; representative images shown in Figs. 6B, 7B, and 8B). In addition, GS-9973 also reduced hepatic hydroxyproline levels all three fibrosis models (Figs. 6D, 7D, and 8D) . GS-9973 did not affect fibrosis development in vehicle control animals (Figs. 6-8 ).
There were no significant differences in liver weight or liver/body weight ratio between GS-9973 treated and vehicle control animals in DEN models (Fig. 7F,  Supporting Fig. S15C,D) . Importantly, we found that GS-9973 significantly decreased the number of HCCs, particularly the number of smaller tumors (<8 mm diameter) after 18 weeks of DEN injury compared to vehicle control (P < 0.05; Fig. 7F, Supporting Fig.  S15E,F (Figs. 6E, 7E, and 8C) . In the BDL model, we found that high dose GS-9973 (10 mg/kg) dramatically decreased jaundice, inhibited proliferation of intrahepatic bile ducts and reduced liver/body weight ratio (all P < 0.01; Fig. 8D ,E) compared to the sham group. Low-dose GS-9973 (2.5 mg/kg) treatment partially rescued hepatic function (ALP, ALT and Glu; all P < 0.05), but did not significantly recover AST, Alb and TBIL levels compared to vehicle control in the BDL model (Supporting Fig. S16F ). Moreover, we demonstrated that GS-9973 inhibited Ki-67 expression compared to vehicle control in the CCl 4 and BDL models (Supporting Fig. S17 ).
Hemodynamic adverse effects have been reported with several SYK inhibitors in some clinical trials. (35) Therefore, we measured systemic arterial blood pressure, portal pressure, liver weight, spleen weight and body weight of normal rats treated with vehicle or the SYK antagonist GS-9973. We did not observe any significant hemodynamic changes following GS-9973 treatment (2.5 and 10 mg/kg), for 2 or 5 weeks in rats, and no effects on liver weight, spleen weight and body weight in mice treated with GS-9973 (5 and 20 mg/ kg) for 4 weeks (Supporting Table S3 ). In addition, there were no effects on hepatic and renal function, or histopathologic changes in murine heart, liver and kidney with GS-9973 treatment (data not shown).
Discussion
Liver fibrosis/cirrhosis is a major health problem worldwide, for which there are currently no approved therapies. (10, 11) Activated HSCs play a central role in liver fibrosis, however, the molecular mechanisms by which HSCs are activated and become fibrogenic are not completely understood. In this study, we found that enhanced SYK expression associated with liver fibrosis/cirrhosis, especially in liver tissues from patients with viral hepatitis and with NASH. Dual immunofluorescence and IHC staining further demonstrated that SYK upregulation is mainly localized to hepatocytes and HSCs. Moreover, our results showed that HBV/HCV infection significantly increased SYK expression in hepatocytes. We demonstrated that the up-regulation of SYK in hepatocytes induced SYK expression in HSCs and promoted GS-9973 reduced the number of tumor nodules, but did not significantly affect body weight or liver weight. Scale bars, 100 lm. Data presented are means 6 SD. NS 5 not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
HSCs activation via crosstalk between cytokines secreted by hepatocytes and HSCs. We also found that the induced expression of SYK in HSCs further promoted HSC activation by increasing the expression of specific TFs associated with HSC activation and proliferation (Fig. 8F) . SYK inhibition by the small- Representative photomicrographs of CK19 immunostaining in liver tissue from BDL rats treated with vehicle or GS-9973. Scale bar, 100 lm. (F) Proposed model of SYK regulation of liver fibrosis through promoting HSC activation and proliferation. Data presented are means 6 SD. NS 5 not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001. molecule inhibitor GS-9973 blocked HSC activation in vitro and significantly reduced fibrogenesis in three independent murine models. SYK may be a potential therapeutic target for liver fibrosis, including in NASH-related liver fibrosis, where there are no approved therapies for NASH in addition to the lack of approved therapies for liver fibrosis.
SYK is a nonreceptor protein tyrosine kinase, which is in clinical development as a therapeutic target for rheumatoid arthritis and lymphocytic leukemia. (15, 20) SYK gene codes two transcripts, the full-length SYK(L) and an alternatively spliced SYK transcript, named SYK(S). The SYK(S) isoform lacks a 69-bp sequence, generating a truncated isoform lacking 23 residues in interdomain B (IDB). (36) We previously found that two isoforms of SYK exerted opposing functions in HCC. (36, 37) SYK(L) was mainly expressed in non-tumor liver tissue, and was significantly downregulated in HCC. In contrast, SYK(S) expression was very low in non-tumor tissue. Moreover, SYK(L) suppressed the proliferation and invasiveness of HCC cells, while SYK(S) possessed oncogenic activities and promoted invasion and metastases of HCC cells. (36, 37) We found both SYK(L) and SYK(S) overexpression promoted the activation of HSCs and chemicallyinduced murine liver fibrosis stimulated SYK(L)/(S) expression up-regulation. We found that SYK(L), but not SYK(S) played a major role in liver fibrosis in vitro. SYK(L) exerted greater effects on liver fibrosis development compared to SYK(S) in all three of our animal fibrosis models. We speculate that expression levels of these two SYK isoforms may be useful markers to monitor HCC development.
In this study, we found that four SYK inhibitors GS-9973, PRT062607, R406 and BAY-61-3606 (data of R406 and BAY-61-3606 not shown) had significant in vitro antifibrotic activity. GS-9973 was the most potent SYK inhibitor for blocking SYK phosphorylation at Y525/526. Our data show that GS-9973 significantly reduced liver fibrosis and rescued hepatic function. Furthermore, GS-9973 (10 mg/kg) dramatically decreased jaundice and serum TBIL, inhibited proliferation of intrahepatic bile ducts and reduced liver/body weight ratio in BDL rats. We speculate that this phenomenon is mainly due to the antifibrotic and hepatoprotective effects of GS-9973. However, the specific mechanism underlying this phenomenon is not fully elucidated. Further studies to explore the mechanism by which SYK inhibition by GS-9973 leads to lower bilirubin levels in the surgical BDL model are warranted. In addition, we found that GS-9973 decreased the number of HCC tumors in DEN-induced rat fibrosis model. These results suggest that targeting SYK could help to prevent HCC. Further studies to investigate whether SYK inhibition prevents intrahepatic recurrence in patients with a history of HCC are warranted.
We conclude that SYK is a key molecule for HSC activation and liver fibrogenesis. SYK-targeted treatment with a SYK inhibitor resulted in a potent antifibrotic effect without concomitant hemodynamic changes . Therefore, SYK is an attractive therapeutic target for liver fibrosis. We therefore propose a model of SYK regulating liver fibrosis (Fig. 8F) . Chronic liver injury (e.g., HBV, HCV, alcohol) increases expression of SYK in hepatocytes, which promotes HSC activation and up-regulates SYK expression in HSCs via crosstalk. Up-regulated SYK in HSCs further promotes HSC activation by increasing the expression of TFs associated with their activation (i.e., CBP, MYB, MYC) and by enhancing the expression of genes associated with HSC proliferation (MYC and CCND1). The up-regulated SYK further promotes the progression of liver fibrosis/cirrhosis and hepatocarcinogenesis.
